Literature DB >> 28659333

Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports.

Glenda Grossi1, Mauro Viganò2, Floriana Facchetti1, Sara Labanca2, Alessandro Loglio1, Anna Dodero3, Vittorio Montefusco3, Paolo Corradini3, Anna Cafro4, Roberto Cairoli4, Massimo Colombo5, Pietro Lampertico6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28659333      PMCID： PMC5622877          DOI： 10.3324/haematol.2017.168609

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Occult hepatitis B virus infection.

Authors:  Giovanni Raimondo; Teresa Pollicino; Irene Cacciola; Giovanni Squadrito
Journal:  J Hepatol       Date:  2006-11-07       Impact factor: 25.083

2.  Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification.

Authors:  Wai-Kay Seto
Journal:  World J Hepatol       Date:  2015-04-28

3.  Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Ritsuro Suzuki; Takashi Watanabe; Masanobu Nakata; Hirotaka Takasaki; Noriyasu Fukushima; Takuya Fukushima; Yukiyoshi Moriuchi; Kuniaki Itoh; Kisato Nosaka; Ilseung Choi; Masashi Sawa; Rumiko Okamoto; Hideki Tsujimura; Toshiki Uchida; Sachiko Suzuki; Masataka Okamoto; Tsutomu Takahashi; Isamu Sugiura; Yasushi Onishi; Mika Kohri; Shinichiro Yoshida; Rika Sakai; Minoru Kojima; Hiroyuki Takahashi; Akihiro Tomita; Dai Maruyama; Yoshiko Atsuta; Eiji Tanaka; Takayo Suzuki; Tomohiro Kinoshita; Michinori Ogura; Masashi Mizokami; Ryuzo Ueda
Journal:  Clin Infect Dis       Date:  2015-05-01       Impact factor: 9.079

4.  Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.

Authors:  C Cerva; L Colagrossi; G Maffongelli; R Salpini; D Di Carlo; V Malagnino; A Battisti; A Ricciardi; M Pollicita; A Bianchi; A Picardi; L Cudillo; R Cerretti; G De Angelis; M Cantonetti; M Andreoni; C F Perno; W Arcese; V Svicher; L Sarmati
Journal:  Clin Microbiol Infect       Date:  2016-07-27       Impact factor: 8.067

5.  Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.

Authors:  Chiun Hsu; Hsiao-Hui Tsou; Shyh-Jer Lin; Ming-Chung Wang; Ming Yao; Wen-Li Hwang; Woei-Yau Kao; Chang-Fang Chiu; Sheng-Fung Lin; Johnson Lin; Cheng-Shyong Chang; Hwei-Fang Tien; Tsang-Wu Liu; Pei-Jer Chen; Ann-Lii Cheng
Journal:  Hepatology       Date:  2014-04-14       Impact factor: 17.425

6.  High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy.

Authors:  Roberto Castelli; Laurenzia Ferraris; Giuseppe Pantaleo; Giorgio Lambertenghi Deliliers; Marco Cicardi
Journal:  Dig Liver Dis       Date:  2016-08-20       Impact factor: 4.088

7.  Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.

Authors:  Jeong-Ju Yoo; Eun Ju Cho; Young Youn Cho; Minjong Lee; Dong Hyeon Lee; Yuri Cho; Jeong-Hoon Lee; Su Jong Yu; Sung-Soo Yoon; Jung-Hwan Yoon; Yoon Jun Kim
Journal:  Liver Int       Date:  2015-06-19       Impact factor: 5.828

Review 8.  Prophylaxis and treatment of hepatitis B in immunocompromised patients.

Authors:  A Marzano; E Angelucci; P Andreone; M Brunetto; R Bruno; P Burra; P Caraceni; B Daniele; V Di Marco; F Fabrizi; S Fagiuoli; P Grossi; P Lampertico; R Meliconi; A Mangia; M Puoti; G Raimondo; A Smedile
Journal:  Dig Liver Dis       Date:  2007-03-26       Impact factor: 4.088

9.  Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

Authors:  Yi-Hsiang Huang; Liang-Tsai Hsiao; Ying-Chung Hong; Tzeon-Jye Chiou; Yuan-Bin Yu; Jyh-Pyng Gau; Chun-Yu Liu; Muh-Hwa Yang; Cheng-Hwai Tzeng; Pui-Ching Lee; Han-Chieh Lin; Shou-Dong Lee
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

10.  Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.

Authors:  Akihiro Tamori; Masayuki Hino; Etsushi Kawamura; Hideki Fujii; Sawako Uchida-Kobayashi; Hiroyasu Morikawa; Hirohisa Nakamae; Masaru Enomoto; Yoshiki Murakami; Norifumi Kawada
Journal:  J Gastroenterol Hepatol       Date:  2014-09       Impact factor: 4.029
View more
  2 in total

1.  Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors:  Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal:  Blood       Date:  2018-10-19       Impact factor: 22.113

Review 2.  Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma.

Authors:  Yutaka Tsukune; Makoto Sasaki; Norio Komatsu
Journal:  Cancers (Basel)       Date:  2019-11-19       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.